Eli Lilly Shares Spike On Patent Victory


The U.S. Patent and Trademark Office ruled in favor of Eli Lilly and Co Thursday in an inter partes review of the '209 patent for Alimta, a chemotherapy drug for lung cancer. "Based on the record before us, we conclude that petitioner has failed to demonstrate by a preponderance of the evidence that claims 122 of the '209 patent are unpatentable," the written decision said.



from Biotech News